Candel Therapeutics Inc. (CADL)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Candel Therapeutics: An Overlooked Late-Stage Biotech With Real Potential
Candel Therapeutics is transitioning from a high-risk clinical-stage biotech to a late-stage oncology company with a BLA-directed lead asset. CAN-2409 has achieved positive Phase III results in localized prostate cancer, with additional promising data in NSCLC and PDAC, supporting a 'pipeline in a product' thesis. CADL's valuation appears overly pessimistic given its regulatory catalysts, improved financial runway into Q1 2028, and multiple clinical-stage assets.
Wall Street Analysts Believe Candel Therapeutics (CADL) Could Rally 148.48%: Here's is How to Trade
The mean of analysts' price targets for Candel Therapeutics (CADL) points to a 148.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Candel Therapeutics, Inc. (CADL) Discusses Extended Follow-Up Data From Phase 3 Trial of aglatimagene besadenovec in Localized Prostate Cancer Transcript
Candel Therapeutics, Inc. (CADL) Discusses Extended Follow-Up Data From Phase 3 Trial of aglatimagene besadenovec in Localized Prostate Cancer Transcript
Candel Therapeutics teams up with EVERSANA to prep for prostate cancer drug launch
Candel Therapeutics Inc (NASDAQ:CADL), a clinical-stage biopharmaceutical company developing multimodal immunotherapies for cancer patients, has signed a commercialization agreement with EVERSANA, a global commercialization services provider, to gear up for the potential US launch of aglatimagene besadenovec (CAN-2409) for intermediate- to high-risk, localized prostate cancer. Under the deal, EVERSANA will deliver an integrated range of services covering data and analytics, medical affairs, market access, and field operations.
Candel Therapeutics: 'Cancer Vaccine' Buy Thesis Appears Compelling
Candel Therapeutics, Inc. seems positioned for significant upside as its lead asset, aglatimagene, nears key prostate cancer Phase 3 readouts and a potential BLA filing. CADL's aglatimagene has demonstrated statistically significant improvements in disease-free survival and safety, supporting a strong case for FDA approval and commercial launch in 2027. Recent analyst price targets ($26–$30) and market excitement reflect confidence in CADL's late-stage pipeline, especially given the $2.9bn peak revenue estimate for aglatimagene.
Candel Therapeutics reports extended survival in Phase 2a lung cancer trial of CAN-2409
Candel Therapeutics Inc (NASDAQ:CADL) has reported updated clinical data showing extended survival outcomes from its ongoing phase 2a trial of aglatimagene besadenovec (CAN-2409) in patients with advanced non-small cell lung cancer (NSCLC) who had previously shown an inadequate response to immune checkpoint inhibitors (ICIs). The additional 12 months of follow-up data indicate that 50% of the 46 patients in the per-protocol population remained alive at 24 months after treatment.
Candel Therapeutics strengthens balance sheet as lead cancer therapy advances
Candel Therapeutics Inc (NASDAQ:CADL) is advancing plans to bring its lead cancer immunotherapy toward potential commercialization, outlining new phase 3 trials and a planned regulatory filing while reporting its fourth quarter and full-year 2025 financial results. “During the quarter, we made meaningful progress across our clinical pipeline and pre-commercial readiness, entering 2026 with strong momentum and a robust set of potential value-driving catalysts,” Candel CEO Paul Peter Tak said in a statement.
Candel Therapeutics prices $100M public offering
Candel Therapeutics Inc (NASDAQ:CADL) told investors on Thursday it has priced its previously disclosed public offering of about 18.3 million shares at $5.45 per share. The clinical-stage biopharmaceutical company said the offering is expected to generate gross proceeds of about $100 million, before deducting underwriting discounts, commissions and other expenses.
Candel Therapeutics inks $100M funding agreement with RTW Investments, launches $100M public offering
Candel Therapeutics Inc (NASDAQ:CADL) on Thursday announced two financing initiatives to support the potential US launch of its cancer therapy aglatimagene besadenovec (CAN-2409) for intermediate- to high-risk localized prostate cancer: a $100 million royalty funding agreement with RTW Investments and a proposed $100 million public offering of common stock. The royalty funding agreement provides Candel with non-dilutive financing to strengthen its balance sheet for a potential commercial launch of aglatimagene in the United States, subject to US Food and Drug Administration (FDA) approval.
New Strong Sell Stocks for January 20th
DAR, CADL and DRTS have been added to the Zacks Rank #5 (Strong Sell) List on January 20, 2026.
Candel Therapeutics highlights third quarter milestones across cancer immunotherapy pipeline
Candel Therapeutics Inc (NASDAQ:CADL) reported encouraging clinical progress across its cancer immunotherapy pipeline, along with the release of its third quarter 2025 financial results. The company recently presented new Phase 3 subgroup analyses of CAN-2409 in localized prostate cancer showing statistically significant improvement in disease-free survival and updated survival data from its Phase 1b CAN-3110 trial in recurrent high-grade glioma, underscoring the potential of its multimodal immunotherapies.
Candel Therapeutics secures $130M to fund lead program – ICYMI
Candel Therapeutics Inc (NASDAQ:CADL) CEO Dr. Paul Peter Tak talked with Proactive about the company's recently secured $130 million term loan facility with Trinity Capital.
